These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21311691)

  • 1. Vitamin D and responses to inhaled fluticasone in severe chronic obstructive pulmonary disease.
    Kunisaki KM; Rector TS
    Int J Chron Obstruct Pulmon Dis; 2011 Jan; 6():29-34. PubMed ID: 21311691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.
    Kunisaki KM; Rice KL; Janoff EN; Rector TS; Niewoehner DE
    Ther Adv Respir Dis; 2008 Apr; 2(2):55-64. PubMed ID: 19124359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
    Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Lung; 2006; 184(4):217-22. PubMed ID: 17006748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
    Cheng SL; Lin CH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids.
    Wolfe J; Rooklin A; Grady J; Munk ZM; Stevens A; Prillaman B; Duke S; Harding S
    J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1153-61. PubMed ID: 10856150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, determinants and clinical correlates of vitamin D deficiency in patients with Chronic Obstructive Pulmonary Disease in London, UK.
    Jolliffe DA; James WY; Hooper RL; Barnes NC; Greiller CL; Islam K; Bhowmik A; Timms PM; Rajakulasingam RK; Choudhury AB; Simcock DE; Hyppönen E; Walton RT; Corrigan CJ; Griffiths CJ; Martineau AR
    J Steroid Biochem Mol Biol; 2018 Jan; 175():138-145. PubMed ID: 28161533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
    Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance-associated protein 1 and lung function decline with or without long-term corticosteroids treatment in COPD.
    Budulac SE; Postma DS; Hiemstra PS; Lapperre TS; Kunz LI; Vonk JM; Marike Boezen H; Timens W;
    Eur J Pharmacol; 2012 Dec; 696(1-3):136-42. PubMed ID: 22982023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.
    Postma DS; Roche N; Colice G; Israel E; Martin RJ; van Aalderen WM; Grigg J; Burden A; Hillyer EV; von Ziegenweidt J; Gopalan G; Price D
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1163-86. PubMed ID: 25378918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.
    Miller DP; Watkins SE; Sampson T; Davis KJ
    Phys Sportsmed; 2010 Dec; 38(4):19-27. PubMed ID: 21150138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.
    Rodriguez-Roisin R; Tetzlaff K; Watz H; Wouters EF; Disse B; Finnigan H; Magnussen H; Calverley PM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1973-81. PubMed ID: 27578972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
    Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.